363 documents

Read All
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Affymax management update

Affymax Inc. (OTCQB:AFFY), Cupertino, Calif.   Business: Hematology   Hired: Jonathan Couchman as president, CEO and a director, formerly CEO, CFO and chairman of Myrexis Inc.  ...
Read More
07:00 , Oct 13, 2014 |  BioCentury  |  Strategy

Streamlining Takeda's Profit Story

After spending a decade growing the company via acquisition, Takeda Pharmaceutical Co. Ltd. is now focused on getting its costs in line with its global pharma peers. But to grow EPS in line with Street...
Read More
01:47 , Aug 20, 2014 |  BC Extra  |  Financial News

Dermatology play Dermira raises $51 million in series C

Dermira Inc. (Redwood City, Calif.) raised $51 million in a series C round and announced a number of management changes and board appointments. The C round came from existing investors Bay City Capital; New Enterprise...
Read More
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
Read More
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

Affymax hematology news

Affymax said its board approved a plan to liquidate and dissolve the company. The company said the estimated shareholder payout is about $4 million, or “a few cents per share” based on 37.5 million shares...
Read More
07:00 , Jun 30, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Basilea Pharmaceutica AG (SIX:BSLN) fell CHF9.10 to CHF104.90 last week after it said FDA confirmed additional Phase III data would be required to support U.S. approval of ceftobiprole to treat pneumonia. The company...
Read More
00:24 , Jun 25, 2014 |  BC Extra  |  Company News

Affymax to dissolve

Affymax Inc. (OTCQB:AFFY) said its board approved a plan to liquidate and dissolve the company. The company said the estimated shareholder payout is about $4 million, or "a few cents per share" based on 37.5...
Read More
07:00 , Jun 16, 2014 |  BC Week In Review  |  Company News

Affymax, Takeda deal

Takeda is terminating a 2006 deal with Affymax to co-develop and co-commercialize Omontys peginesatide, effective Sept. 10. The pharma also will withdraw an NDA in the U.S. for the once-monthly anemia drug. According to the...
Read More
00:40 , Jun 14, 2014 |  BC Extra  |  Company News

Takeda ends Affymax deal, to pull Omontys NDA

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) is ending a 2006 deal with Affymax Inc. (OTCQB:AFFY) to co-develop and co-commercialize Omontys peginesatide, effective Sept. 10. The pharma said it also will withdraw an NDA in the U.S....
Read More
07:00 , Mar 31, 2014 |  BC Week In Review  |  Company News

ChemoCentryx management update

ChemoCentryx Inc. (NASDAQ:CCXI), Mountain View, Calif.   Business: Autoimmune, Inflammation, Cancer   Hired: Anne-Marie Duliege as EVP, chief of strategic development and head of immuno-oncology, a newly created position, formerly head of research and CMO...
Read More